Published in J Infect Dis on January 15, 2010
West Nile virus infection and immunity. Nat Rev Microbiol (2013) 2.40
Chemokine receptor Ccr2 is critical for monocyte accumulation and survival in West Nile virus encephalitis. J Immunol (2010) 1.58
West Nile Virus: biology, transmission, and human infection. Clin Microbiol Rev (2012) 1.38
The innate immune adaptor molecule MyD88 restricts West Nile virus replication and spread in neurons of the central nervous system. J Virol (2010) 1.38
Targeted DNA mutagenesis for the cure of chronic viral infections. J Virol (2012) 1.36
Confidence intervals that match Fisher's exact or Blaker's exact tests. Biostatistics (2009) 1.33
Host genetic risk factors for West Nile virus infection and disease progression. PLoS One (2011) 1.22
Clinical use of CCR5 inhibitors in HIV and beyond. J Transl Med (2011) 1.15
Genetic diversity in the collaborative cross model recapitulates human West Nile virus disease outcomes. MBio (2015) 1.04
A role for the chemokine RANTES in regulating CD8 T cell responses during chronic viral infection. PLoS Pathog (2011) 1.03
Innate immune control of West Nile virus infection. Cell Microbiol (2011) 1.02
Differential virulence and pathogenesis of West Nile viruses. Viruses (2013) 0.99
CD8+ T cells use TRAIL to restrict West Nile virus pathogenesis by controlling infection in neurons. J Virol (2012) 0.98
Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4). J Med Chem (2011) 0.98
Chemokine receptors as important regulators of pathogenesis during arboviral encephalitis. Front Cell Neurosci (2014) 0.97
Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer. Clin Cancer Res (2013) 0.96
Chemokine control of West Nile virus infection. Exp Cell Res (2011) 0.95
Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. Sci Rep (2015) 0.94
Genetic variants and susceptibility to neurological complications following West Nile virus infection. J Infect Dis (2011) 0.92
Controlling the HIV/AIDS epidemic: current status and global challenges. Front Immunol (2012) 0.92
IL-1R1 signaling regulates CXCL12-mediated T cell localization and fate within the central nervous system during West Nile Virus encephalitis. J Immunol (2014) 0.91
Age-related alterations in immune responses to West Nile virus infection. Clin Exp Immunol (2016) 0.91
Novel approaches and challenges to treatment of central nervous system viral infections. Ann Neurol (2013) 0.90
The chemokine receptor CCR5, a therapeutic target for HIV/AIDS antagonists, is critical for recovery in a mouse model of Japanese encephalitis. PLoS One (2012) 0.87
CCR5 antagonism impacts vaccination response and immune profile in HIV-1 infection. Mol Med (2012) 0.85
Cellular targets for influenza drugs. Nat Biotechnol (2010) 0.84
CD22 is required for protection against West Nile virus Infection. J Virol (2013) 0.83
The contribution of rodent models to the pathological assessment of flaviviral infections of the central nervous system. Arch Virol (2012) 0.83
CCR5 blockade for neuroinflammatory diseases - beyond control of HIV. Nat Rev Neurol (2016) 0.83
Determinants of sexual network structure and their impact on cumulative network measures. PLoS Comput Biol (2012) 0.81
West nile virus. Transfus Med Hemother (2013) 0.81
The neuroimmune response to West Nile virus. J Neurovirol (2013) 0.81
Polymorphisms in chemokine receptor 5 and Toll-like receptor 3 genes are risk factors for clinical tick-borne encephalitis in the Lithuanian population. PLoS One (2014) 0.80
Tissue expression of steroid hormone receptors is associated with differential immune responsiveness. Brain Behav Immun (2010) 0.79
The Interferon-Stimulated Gene Ifi27l2a Restricts West Nile Virus Infection and Pathogenesis in a Cell-Type- and Region-Specific Manner. J Virol (2015) 0.79
Risk factors for West Nile virus infection and disease in populations and individuals. Expert Rev Anti Infect Ther (2015) 0.79
Association between regulated upon activation, normal T cells expressed and secreted (RANTES) -28C/G polymorphism and susceptibility to HIV-1 infection: a meta-analysis. PLoS One (2013) 0.78
The expression of the chemokine receptor CCR5 in tick-borne encephalitis. J Neuroinflammation (2016) 0.78
CCR5 limits cortical viral loads during West Nile virus infection of the central nervous system. J Neuroinflammation (2015) 0.78
Double-edged genetic swords and immunity: lesson from CCR5 and beyond. J Infect Dis (2010) 0.78
Differences in Early Cytokine Production Are Associated With Development of a Greater Number of Symptoms Following West Nile Virus Infection. J Infect Dis (2016) 0.76
Staphylococcus aureus and CCR5: unveiling commonalities in host-pathogen interactions and potential treatment strategies. Future Microbiol (2013) 0.76
Comparison of cytokine expressions in acute myocardial infarction and stable angina stages of coronary artery disease. Int J Clin Exp Med (2015) 0.76
Host genomics in infectious diseases. Infect Chemother (2013) 0.76
Maraviroc Failed to Control Progressive Multifocal Leukoencephalopathy-Associated IRIS in a Patient with Advanced HIV Infection. Case Rep Med (2014) 0.75
Dual Function of Ccr5 during Langat Virus Encephalitis: Reduction in Neutrophil-Mediated Central Nervous System Inflammation and Increase in T Cell-Mediated Viral Clearance. J Immunol (2016) 0.75
Identification of genetic variants associated with susceptibility to West Nile virus neuroinvasive disease. Genes Immun (2016) 0.75
Targeting the chemokine receptor CCR5: good for HIV, what about other viruses? J Infect Dis (2011) 0.75
Genetic Contribution of MHC Class II Genes in Susceptibility to West Nile Virus Infection. PLoS One (2016) 0.75
The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med (1996) 10.62
Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med (2008) 7.31
Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet (2001) 6.49
Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med (2003) 4.95
The West Nile Virus outbreak of 1999 in New York: the Flushing Hospital experience. Clin Infect Dis (2000) 3.86
West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States. Annu Rev Med (2006) 3.68
CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med (2006) 3.57
Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med (2003) 3.37
Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J Exp Med (2005) 3.08
Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis (2008) 2.54
Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing. N Engl J Med (2005) 2.32
The continuing spread of West Nile virus in the western hemisphere. Clin Infect Dis (2007) 2.28
West Nile virus among blood donors in the United States, 2003 and 2004. N Engl J Med (2005) 1.98
A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J Infect Dis (2008) 1.95
Role for CCR5Delta32 protein in resistance to R5, R5X4, and X4 human immunodeficiency virus type 1 in primary CD4+ cells. J Virol (2004) 1.72
Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers. Mol Pharmacol (2004) 1.69
Negative association between the chemokine receptor CCR5-Delta32 polymorphism and rheumatoid arthritis: a meta-analysis. Genes Immun (2006) 1.46
CCR5: no longer a "good for nothing" gene--chemokine control of West Nile virus infection. Trends Immunol (2006) 1.20
Phenotypic expressions of CCR5-delta32/delta32 homozygosity. J Acquir Immune Defic Syndr (1999) 1.05
Self-reported symptoms associated with West Nile virus infection in RNA-positive blood donors. Transfusion (2006) 1.04
Genotype and allele frequency of a 32-base pair deletion mutation in the CCR5 gene in various ethnic groups: absence of mutation among Asians and Pacific Islanders. Int J Infect Dis (1999) 0.94
Mapping and analysis of West Nile virus-specific monoclonal antibodies: prospects for vaccine development. Expert Rev Vaccines (2007) 0.92
CCR5-delta 32 gene deletion in HIV-1 infected patients. Lancet (1997) 0.92
Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med (2012) 5.87
Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis (2005) 5.14
Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol (2007) 4.96
Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA (2003) 3.90
International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev (2009) 3.65
CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med (2006) 3.57
Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation (2003) 3.55
Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med (2003) 3.37
Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J Exp Med (2005) 3.08
Formyl-peptide receptors revisited. Trends Immunol (2002) 3.08
Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol (2008) 2.90
The United States Trypanosoma cruzi Infection Study: evidence for vector-borne transmission of the parasite that causes Chagas disease among United States blood donors. Transfusion (2012) 2.69
Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis (2008) 2.54
A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion (2005) 2.51
Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion (2010) 2.39
Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest (2003) 2.27
Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. Blood (2007) 2.21
Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis (2005) 2.12
International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev (2013) 2.11
High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis (2011) 2.10
The safety of the blood supply--time to raise the bar. N Engl J Med (2015) 2.08
Probability of viremia with HBV, HCV, HIV, and HTLV among tissue donors in the United States. N Engl J Med (2004) 2.08
CX3CR1-dependent renal macrophage survival promotes Candida control and host survival. J Clin Invest (2013) 2.00
Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol (2002) 1.98
West Nile virus among blood donors in the United States, 2003 and 2004. N Engl J Med (2005) 1.98
Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther (2002) 1.96
HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. Proc Natl Acad Sci U S A (2008) 1.95
Organ-specific innate immune responses in a mouse model of invasive candidiasis. J Innate Immun (2010) 1.94
The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol (2003) 1.92
Chemokine receptor CX3CR1 mediates skin wound healing by promoting macrophage and fibroblast accumulation and function. J Immunol (2008) 1.90
IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood (2004) 1.82
Dengue viremia in blood donors identified by RNA and detection of dengue transfusion transmission during the 2007 dengue outbreak in Puerto Rico. Transfusion (2012) 1.81
Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS Pathog (2009) 1.81
West Nile virus infections projected from blood donor screening data, United States, 2003. Emerg Infect Dis (2006) 1.76
CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation (2005) 1.76
Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. Cell Host Microbe (2011) 1.74
Role for CCR5Delta32 protein in resistance to R5, R5X4, and X4 human immunodeficiency virus type 1 in primary CD4+ cells. J Virol (2004) 1.72
Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. J Exp Med (2006) 1.72
Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med (2011) 1.69
A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood (2014) 1.66
The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome. Blood (2011) 1.65
A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail (2003) 1.60
Chemokine receptor Ccr2 is critical for monocyte accumulation and survival in West Nile virus encephalitis. J Immunol (2010) 1.58
Development and persistence of West Nile virus-specific immunoglobulin M (IgM), IgA, and IgG in viremic blood donors. J Clin Microbiol (2005) 1.56
Transmission of HIV and hepatitis C virus from a nursing home patient to a health care worker. Am J Infect Control (2003) 1.53
Current value of serologic test for syphilis as a surrogate marker for blood-borne viral infections among blood donors in the United States. Transfusion (2009) 1.52
Unifying the spatial epidemiology and molecular evolution of emerging epidemics. Proc Natl Acad Sci U S A (2012) 1.52
Chemokine receptor Ccr1 drives neutrophil-mediated kidney immunopathology and mortality in invasive candidiasis. PLoS Pathog (2012) 1.49
Complete genome sequence of a tenth human polyomavirus. J Virol (2012) 1.48
Viral marker rates among blood donors before and after the terrorist attacks on the United States on September 11, 2001. Transfusion (2002) 1.48
Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J Immunol (2004) 1.45
Distinct mechanisms of agonist-induced endocytosis for human chemokine receptors CCR5 and CXCR4. Mol Biol Cell (2003) 1.44
Lysis of endogenously infected CD4+ T cell blasts by rIL-2 activated autologous natural killer cells from HIV-infected viremic individuals. PLoS Pathog (2008) 1.44
Dengue virus in blood donations, Puerto Rico, 2005. Transfusion (2008) 1.43
Genetic diversity of recently acquired and prevalent HIV, hepatitis B virus, and hepatitis C virus infections in US blood donors. J Infect Dis (2012) 1.43
Chemokine regulation of inflammation during acute viral infection. Curr Opin Allergy Clin Immunol (2003) 1.42
ASSESSING SURROGATE ENDPOINTS IN VACCINE TRIALS WITH CASE-COHORT SAMPLING AND THE COX MODEL. Ann Appl Stat (2008) 1.41
Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10. Blood (2006) 1.41
Chemokine receptor CCR1 but not CCR5 mediates leukocyte recruitment and subsequent renal fibrosis after unilateral ureteral obstruction. J Am Soc Nephrol (2004) 1.41
Patterns of age- and sex-specific prevalence of major blood-borne infections in United States blood donors, 1995 to 2002: American Red Cross blood donor study. Transfusion (2004) 1.36
Chagas disease and the US blood supply. Curr Opin Infect Dis (2008) 1.35
On the mechanism and significance of ligand-induced internalization of human neutrophil chemokine receptors CXCR1 and CXCR2. J Biol Chem (2004) 1.34
Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology (2003) 1.34
A highly sensitive and dynamic immunofluorescent cytometric bead assay for the detection of HIV-1 p24. J Virol Methods (2009) 1.31
Pre-ART levels of inflammation and coagulation markers are strong predictors of death in a South African cohort with advanced HIV disease. PLoS One (2012) 1.31
Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation. J Am Soc Nephrol (2007) 1.31
Identification of formyl peptides from Listeria monocytogenes and Staphylococcus aureus as potent chemoattractants for mouse neutrophils. J Immunol (2008) 1.30
G-CSF-induced spleen size changes in peripheral blood progenitor cell donors. Transfusion (2003) 1.29
CXCR4-transgene expression significantly improves marrow engraftment of cultured hematopoietic stem cells. Stem Cells (2004) 1.29
Enhanced function with decreased internalization of carboxy-terminus truncated CXCR4 responsible for WHIM syndrome. Exp Hematol (2005) 1.28
Nanoparticle-Based biobarcode amplification assay (BCA) for sensitive and early detection of human immunodeficiency type 1 capsid (p24) antigen. J Acquir Immune Defic Syndr (2007) 1.27
Chemokine receptor CX3CR1 regulates renal interstitial fibrosis after ischemia-reperfusion injury. Am J Pathol (2006) 1.26
Xenotropic murine leukemia virus-related virus (XMRV) and blood transfusion: report of the AABB interorganizational XMRV task force. Transfusion (2011) 1.26
Trypanosoma cruzi infection in North America and Spain: evidence in support of transfusion transmission. Transfusion (2012) 1.26
West Nile fever characteristics among viremic persons identified through blood donor screening. J Infect Dis (2010) 1.26
Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations. Transfus Med Rev (2011) 1.26
Transfusion-transmitted infectious diseases. Biologicals (2009) 1.25
Correlates of hepatitis C virus (HCV) RNA negativity among HCV-seropositive blood donors. Transfusion (2006) 1.22
Chemotaxis and calcium responses of phagocytes to formyl peptide receptor ligands is differentially regulated by cyclic ADP ribose. J Immunol (2004) 1.22
HIV-1 pathogenesis differs in rectosigmoid and tonsillar tissues infected ex vivo with CCR5- and CXCR4-tropic HIV-1. AIDS (2007) 1.22
Cluster without fluster: The effect of correlated outcomes on inference in randomized clinical trials. Stat Med (2008) 1.21